Printer Friendly

GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.

GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30) has announced that the U.S. Patent and Trademark Office has issued a patent with claims covering RGB-286199, cell cycle inhibitor, to GPC Biotech.

The patent (U.S. Patent No. 6,753,329) claims the composition of matter of a family of cell cycle inhibitors that includes RGB-286199. Claims also include pharmaceutical compositions (the compound as a medicinal product), as well as methods of treating certain diseases, including cancer. The basic term of the patent will expire in late 2022. International equivalents of this patent are pending in other major markets, including Europe, Japan and Canada.

"GPC Biotech has extensive expertise in the cell cycle field, and the issuance of this patent strengthens our position in this family of small molecule compounds that may be important in the area of cell cycle control and anti-cancer drug development," said Sebastian Meier-Ewert, Ph.D., chief scientific officer. "Our cell cycle inhibitor, RGB-286199, has made solid progress over the past year, and our goal is to complete pre-clinical development work on this compound in the first half of 2005."

About RGB-286199 cell cycle inhibitor

The cell cycle is a key cellular process that fails to function normally in cancer development. Cyclin-dependent kinases (Cdks) are proteins that are involved in the regulation of the cell cycle. At least four different Cdks control various key events during the cell cycle. RGB-286199 is a potent inhibitor of all of these Cdks, inhibiting cell division and inducing cell death in cancer cells. The compound has also been shown to inhibit other kinases that have been associated with the development of cancer. Anticancer activity of RGB-286199 has been demonstrated in animal models of ovarian, prostate and colon cancer.

GPC Biotech is currently planning additional toxicology studies, as well as studies to determine appropriate dosing and administration schedules. The company's goal is to complete pre-clinical development work on RGB-286199 in the first half of 2005 and, if successful, GPC Biotech anticipates advancing the drug candidate into clinical trials thereafter.

GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs. The company's lead product candidate - satraplatin - is currently in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer primarily in the U.S. and Europe, following successful completion of a Special Protocol Assessment by the U.S. FDA and receipt of a Scientific Advice letter from the European regulatory authority, EMEA. The FDA has also granted fast track designation to satraplatin for this indication. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. Other anticancer programs in development include a monoclonal antibody and a cell cycle inhibitor. The company is leveraging its drug discovery technologies to elucidate the mechanisms-of-action of drug candidates and to support the growth of its drug pipeline. The company has formed successful alliances with a number of pharmaceutical and biotechnology firms. For example, the company has a multi-year alliance with ALTANA Pharma AG to establish the ALTANA Research Institute in the U.S., which provides GPC Biotech with revenues until 2007. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The company's wholly owned U.S. subsidiary has research sites in Waltham, Massachusetts and Princeton, New Jersey.

For additional information, visit http://www.gpc-biotech.com or call 781/890 9007, ext. 267.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:4EUGE
Date:Aug 1, 2004
Words:551
Previous Article:DECODE INITIATES PHASE IIA CLINICAL TRIAL FOR DG031.
Next Article:RANBAXY LAUNCHES RANICLOR CHEWABLE CEPHALOSPORIN TABLET.
Topics:


Related Articles
GERON REGAINS RIGHTS FOR TELOMERASE INHIBITORS.
Cancer drugs may also thwart obesity. (Fat Chance).
Assay to reveal health role of compounds.
CYCLACEL'S CYC202 INDUCES CANCER CELLS TO COMMIT SUICIDE.
GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.
GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.
GPC BIOTECH PRESENTS NEW SATRAPLATIN DATA AT AACR.
Enzyme stopper combats cancers.
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters